Synergy CHC (SNYR)
Market Price (5/6/2026): $0.326 | Market Cap: $3.7 MilSector: Health Care | Industry: Health Care Distributors
Synergy CHC (SNYR)
Market Price (5/6/2026): $0.326Market Cap: $3.7 MilSector: Health CareIndustry: Health Care Distributors
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -77% Megatrend and thematic driversMegatrends include Health & Wellness Trends. Themes include Nutritional Supplements, Functional Foods & Beverages, and Organic & Natural Products. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% | Penny stockMkt Price is 0.3 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -1.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5.9% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 650% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -13%, Rev Chg QQuarterly Revenue Change % is -41% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -8.5%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -8.5% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -336% Key risksSNYR key risks include [1] severe financial instability and ongoing shareholder dilution, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -77% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends. Themes include Nutritional Supplements, Functional Foods & Beverages, and Organic & Natural Products. |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% |
| Penny stockMkt Price is 0.3 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -1.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5.9% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 650% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -13%, Rev Chg QQuarterly Revenue Change % is -41% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -8.5%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -8.5% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -336% |
| Key risksSNYR key risks include [1] severe financial instability and ongoing shareholder dilution, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Deteriorating Financial Performance in Q4 and Full-Year 2025.
Synergy CHC reported a significant decline in its financial results for the fourth quarter and full year ended December 31, 2025, which were released on April 1, 2026. Net revenue for Q4 2025 decreased by 41% year-over-year to $6.07 million, down from $10.27 million in Q4 2024. For the full year 2025, revenue fell 13% to $30.38 million from $34.83 million in 2024. This poor performance led to a substantial full-year net loss of $12.34 million in 2025, a stark contrast to a net income of $2.12 million in 2024. The market reacted negatively to these results, with the stock declining 20.93% on the day of the announcement.
2. Significant One-Time Charges and Impairments.
The company's financial results were heavily impacted by substantial one-time charges and write-offs during Q4 2025. The gross margin for Q4 2025 collapsed to 36.6% from 63.3% in the prior year, primarily due to the termination of a license agreement amounting to $2.9 million and a $1.04 million write-off of obsolete inventory. Furthermore, operating expenses surged by 202% in the fourth quarter of 2025 due to additional one-time items, including a $6.66 million allowance for bad debt and a $0.9 million write-off of prepaid media credits.
Show more
Stock Movement Drivers
Fundamental Drivers
The -82.6% change in SNYR stock from 1/31/2026 to 5/5/2026 was primarily driven by a -77.8% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5052026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.87 | 0.33 | -82.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 35 | 30 | -12.2% |
| P/S Multiple | 0.5 | 0.1 | -77.8% |
| Shares Outstanding (Mil) | 10 | 11 | -10.4% |
| Cumulative Contribution | -82.6% |
Market Drivers
1/31/2026 to 5/5/2026| Return | Correlation | |
|---|---|---|
| SNYR | -82.6% | |
| Market (SPY) | 3.6% | 2.3% |
| Sector (XLV) | -5.7% | 13.1% |
Fundamental Drivers
The -86.1% change in SNYR stock from 10/31/2025 to 5/5/2026 was primarily driven by a -70.9% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5052026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.34 | 0.33 | -86.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 41 | 30 | -26.7% |
| P/S Multiple | 0.4 | 0.1 | -70.9% |
| Shares Outstanding (Mil) | 7 | 11 | -34.6% |
| Cumulative Contribution | -86.1% |
Market Drivers
10/31/2025 to 5/5/2026| Return | Correlation | |
|---|---|---|
| SNYR | -86.1% | |
| Market (SPY) | 5.5% | 8.3% |
| Sector (XLV) | 1.6% | 19.0% |
Fundamental Drivers
The -83.3% change in SNYR stock from 4/30/2025 to 5/5/2026 was primarily driven by a -67.0% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5052026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.95 | 0.33 | -83.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 36 | 30 | -16.4% |
| P/S Multiple | 0.4 | 0.1 | -67.0% |
| Shares Outstanding (Mil) | 7 | 11 | -39.4% |
| Cumulative Contribution | -83.3% |
Market Drivers
4/30/2025 to 5/5/2026| Return | Correlation | |
|---|---|---|
| SNYR | -83.3% | |
| Market (SPY) | 30.4% | 11.6% |
| Sector (XLV) | 5.3% | 14.6% |
Fundamental Drivers
The 625.1% change in SNYR stock from 4/30/2023 to 5/5/2026 was primarily driven by a 826.7% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5052026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.04 | 0.33 | 625.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 26 | 30 | 16.8% |
| P/S Multiple | 0.0 | 0.1 | 826.7% |
| Shares Outstanding (Mil) | 8 | 11 | -33.0% |
| Cumulative Contribution | 625.1% |
Market Drivers
4/30/2023 to 5/5/2026| Return | Correlation | |
|---|---|---|
| SNYR | 625.1% | |
| Market (SPY) | 78.7% | -1.1% |
| Sector (XLV) | 14.4% | 3.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SNYR Return | 0% | 0% | 0% | 9678% | -58% | -83% | 616% |
| Peers Return | 23% | -35% | 12% | -28% | 23% | 0% | -21% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 5% | 92% |
Monthly Win Rates [3] | |||||||
| SNYR Win Rate | 0% | 0% | 0% | 8% | 25% | 40% | |
| Peers Win Rate | 62% | 37% | 53% | 45% | 43% | 48% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 40% | |
Max Drawdowns [4] | |||||||
| SNYR Max Drawdown | 0% | 0% | 0% | 0% | -63% | -83% | |
| Peers Max Drawdown | -10% | -47% | -22% | -40% | -28% | -12% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: HLF, USNA, NUS, PBH, NATR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/5/2026 (YTD)
How Low Can It Go
| Event | SNYR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -57.1% | -18.8% |
| % Gain to Breakeven | 132.9% | 23.1% |
| Time to Breakeven | 90 days | 79 days |
| 2020 COVID-19 Crash | ||
| % Loss | -56.9% | -33.7% |
| % Gain to Breakeven | 132.1% | 50.9% |
| Time to Breakeven | 4 days | 140 days |
In The Past
Synergy CHC's stock fell -57.1% during the 2025 US Tariff Shock. Such a loss loss requires a 132.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | SNYR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -57.1% | -18.8% |
| % Gain to Breakeven | 132.9% | 23.1% |
| Time to Breakeven | 90 days | 79 days |
| 2020 COVID-19 Crash | ||
| % Loss | -56.9% | -33.7% |
| % Gain to Breakeven | 132.1% | 50.9% |
| Time to Breakeven | 4 days | 140 days |
In The Past
Synergy CHC's stock fell -57.1% during the 2025 US Tariff Shock. Such a loss loss requires a 132.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Synergy CHC (SNYR)
AI Analysis | Feedback
Synergy CHC is like a mini Procter & Gamble (P&G), but focused on health, beauty, and wellness products.
Think of it as a boutique version of Unilever, specializing in supplements, skincare, and lifestyle items.
AI Analysis | Feedback
- FOCUSfactor: Brain health nutritional supplements designed to support cognitive function.
- Flat Tummy: A range of lifestyle products and accessories, including teas, shakes, lollipops, supplements, apparel, and exercise accessories.
- Hand MD: Anti-aging skincare products, such as serums and creams for exfoliation, skin repair, and rehydration, along with hand soaps and hand sanitizers.
AI Analysis | Feedback
Synergy CHC Corp. (SNYR) primarily sells its consumer health care, beauty, and lifestyle products to individual consumers.
Based on its product offerings and sales channels (including television advertising campaigns and online sales), the company serves the following categories of customers:
- Health and Wellness-Conscious Individuals: This category includes consumers seeking nutritional supplements for brain health (under the FOCUSfactor brand) and general wellness, as well as individuals interested in dietary supplements and shakes for weight management or overall well-being (part of the Flat Tummy brand). These customers are typically proactive about their health and seek products to support specific health goals.
- Beauty and Skincare Enthusiasts: This segment comprises individuals who are interested in anti-aging, skin repair, and rehydration products, such as serums and creams (under the Hand MD brand). These customers often prioritize skincare routines and seek specialized products to maintain or improve their skin's appearance and health.
- Lifestyle-Oriented Consumers: This category encompasses individuals who are drawn to products that support a specific lifestyle, often related to fitness, diet, or personal well-being (under the Flat Tummy brand). This includes customers purchasing items like teas, apparel, and exercise accessories that align with a health-conscious or aspirational lifestyle.
AI Analysis | Feedback
nullAI Analysis | Feedback
Jack Ross, Chairman of the Board, Chief Executive Officer
Jack Ross has served as the Chief Executive Officer and Chairman of Synergy CHC since its inception in October 2014. Under his leadership, Synergy has successfully acquired eight individual brands since 2015. Described as a "lifetime business builder and entrepreneur," he possesses a proven track record across various consumer product verticals. Mr. Ross has also held leadership roles as President & Chief Executive Officer of SportsClick, Inc. (from 2009), Chief Executive Officer of Boombod Ltd. (from 2018), Chief Executive Officer & Director of Gowan Capital, Inc. (from 2011), and Chief Executive Officer of Kenek Brands, Inc. (from 2014). Additionally, he served as a Director for Pure Sports, Inc. (from 2009), Synergy Energy Strips World Wide, Inc. (from 2011), and Rio E Cig, Inc. (from 2011).
Jaime Fickett, Chief Financial Officer
Jaime Fickett was appointed Chief Financial Officer in March 2025, following a period where she served as the Senior Vice President of Finance and Operations from January 2015 to December 2024. Prior to her roles at Synergy CHC, Ms. Fickett was the Chief Financial Officer of Factor Nutrition Labs, LLC, a dietary supplements company, from August 2006 to January 2015. Her career also includes experience in the public accounting sector as an auditor from 1999 to 2006. Ms. Fickett holds a Bachelor of Science in Accounting from the University of Maine and a Master of Science in Accounting from Southern New Hampshire University.
Alfred Baumeler, President
Alfred Baumeler has served as President of Synergy CHC since January 2021. Before this, he was the Executive Vice President of Sales and Marketing for the company from August 2015 to December 2020. His experience also includes a role as Senior Vice President of Marketing for Healthy Natural Systems/Core Science Medica (CSM)/Lifeagen, a nutritional supplement company, from September 2012 to August 2015. From November 2009 to November 2011, Mr. Baumeler was the Senior Vice President and Chief Marketing Officer for Natrol, Inc., a manufacturer of vitamins, minerals, and supplements. He has held other senior positions in Sales and Marketing at companies such as Rexall Sundown, Wyeth, and Novartis. Mr. Baumeler earned a Bachelor of Science in Engineering from Rutgers University and a Master of Business Administration in Marketing and Finance from Columbia Business School.
Larry Pairo, VP of Operations & Supply Chain
Larry Pairo currently serves as the Vice President of Operations & Supply Chain for Synergy CHC Corp.
AI Analysis | Feedback
Key Business Risks for Synergy CHC (SNYR)
- Financial Health and Going Concern Risk: Synergy CHC faces significant financial challenges, including poor financial strength, high leverage, negative shareholder equity, and an Altman Z-score in the distress zone, suggesting a potential risk of bankruptcy. The company has exhibited negative free cash flow and struggles to comfortably cover its interest obligations. Furthermore, repeated equity raises have led to shareholder dilution.
- Concentrated Product Portfolio and Brand Dependence: The company relies heavily on a limited number of brands, such as FOCUSfactor and Flat Tummy. This concentration makes Synergy CHC vulnerable to shifts in consumer preferences or changes in retailer orders, which could significantly impact its revenue and profitability if demand for these key brands declines.
- Intense Competition and Limited Competitive Advantage: Synergy CHC operates in a highly competitive consumer health and wellness market. The company competes with significantly larger entities possessing greater resources, established brand recognition, and wider distribution networks, which can hinder Synergy CHC's ability to maintain and expand market share and sustain profitability.
AI Analysis | Feedback
The rapid proliferation of highly targeted, digitally-native direct-to-consumer (DTC) brands in the health, beauty, and lifestyle sectors that leverage social media, influencer marketing, and subscription models. This challenges Synergy CHC's reliance on traditional retail distribution and television advertising campaigns for key brands like FOCUSfactor and Flat Tummy, as these new entrants can quickly gain market share by establishing direct relationships with consumers and adapting more rapidly to market trends.
AI Analysis | Feedback
Here are the addressable market sizes for Synergy CHC's main products:
FOCUSfactor (Brain Health Nutritional Supplements)
- United States: The U.S. brain health supplements market was valued at USD 3.56 billion in 2024 and is projected to reach USD 6.80 billion by 2030, with a compound annual growth rate (CAGR) of 11.5% from 2025 to 2030. Another estimate places the market at USD 3.63 billion in 2025, expected to reach USD 6.90 billion by 2032, growing at a CAGR of 9.6% from 2025 to 2032.
- Canada: The North America brain health supplements market, which includes Canada, is estimated to grow from US$ 2,786.2 million in 2025 to US$ 4,895.8 million by 2032, with a CAGR of 8.4% during this period.
- United Kingdom: The UK brain health supplements market generated a revenue of USD 381.7 million in 2024 and is expected to reach USD 725.8 million by 2030, with a CAGR of 11.3% from 2025 to 2030. Another report indicates the UK brain supplements market reached US$0.96 billion in 2024 and is expected to reach US$ 2.87 billion by 2032, growing with a CAGR of 14.66% during the forecast period 2025-2032.
Flat Tummy (Weight Loss Supplements)
- United States: The U.S. weight loss supplements market was valued at USD 8.5 billion in 2023. It generated a revenue of USD 8,567.2 million in 2024 and is expected to reach USD 17,973.5 million by 2030, growing at a CAGR of 13.1% from 2025 to 2030.
- Canada: The weight loss supplements market in Canada is expected to reach a projected revenue of US$ 5,025.5 million by 2030, with a CAGR of 11.9% from 2025 to 2030.
- United Kingdom: The UK weight loss supplement market is projected to reach USD 3.46 billion by 2026. The UK market for weight loss supplements is expected to grow at a CAGR of 19.7% from 2025 to 2035.
Hand MD (Anti-Aging Skincare Products)
- United States: The U.S. anti-aging products market size was estimated at USD 14.05 billion in 2024 and is projected to reach USD 27.44 billion by 2033, growing at a CAGR of 8.0% from 2025 to 2033. The topical skincare segment held approximately a 48% share in the U.S. anti-aging market in 2024.
- Canada: The Canada anti-aging products market reached US$793.11 million in 2024 and is expected to reach US$1247.02 million by 2032, growing with a CAGR of 5.82% during the forecast period 2025-2032.
- United Kingdom: The UK anti-aging products market size was estimated at USD 3.57 billion in 2024 and is expected to reach USD 6.41 billion by 2033, growing at a CAGR of 7.1% from 2025 to 2033. The UK skincare industry as a whole is worth over $4.1 billion as of 2024.
AI Analysis | Feedback
Synergy CHC Corp. (SNYR) is anticipated to drive future revenue growth over the next two to three years through several key initiatives:
- Expansion of the Functional Beverage Business: The company is rapidly expanding its Ready-To-Drink (RTD) functional beverage business by signing new Direct Store Distribution (DSD) networks with an aim for an all-state strategy in the near future. This expansion includes significant new distribution partnerships with major convenience store chains like EG of America (over 1,600 locations) and retailers like Wakefern Food Group (365 locations), as well as regional distributors such as AlaBev in the Southeast U.S. Synergy CHC is also increasing its sales and service personnel to accelerate the growth of its RTD business in convenience stores and has accumulated over 3 million cans of drink inventory for 2026.
- International Market Expansion: Synergy CHC is actively pursuing international expansion for its FOCUSfactor brand and RTD beverages. The company plans to enter three new international markets, has established a subsidiary in Mexico, and has expanded its license agreement for FocusFactor to include Turkey. Additionally, new market entries in Australia and Taiwan are expected to accelerate revenue in the latter half of 2025 and beyond. Recent developments also include the expansion of FOCUSfactor functional beverage distribution across Canada through partnerships with Walmart Canada and McKesson Canada.
- Growth of the Core FOCUSfactor Supplement Business: The flagship FOCUSfactor brain health supplement continues to be a key driver, with the brand being recognized as the number one pharmacist-recommended OTC memory supplement for 2025-2026, which reinforces its market position and brand confidence. Anticipated progress in sales, product development, and overall market expansion for the FOCUSfactor brand is expected to enhance future revenues. Analysts also recognize large market opportunities for the company's brain health supplements.
- Strategic Distribution Partnerships in North America: The company has secured major distribution wins and expanded its network across North America. This includes a national item authorization from Core Mark, providing access to over 50,000 retail locations. Further expansion of its DSD network through new partnerships in regions like Maine and Pennsylvania is anticipated to boost sales growth for FOCUSfactor products in the Northeast market.
AI Analysis | Feedback
Share Repurchases
- Synergy CHC Corp. has made no share repurchases over the last 3-5 years, with share buybacks for SNYR stock recorded as $0.00.
Share Issuance
- In October 2024, Synergy CHC Corp. completed an Initial Public Offering (IPO) of 1,150,000 shares at $9.00 per share, resulting in net proceeds of approximately $8.4 million. These proceeds were primarily used to repay related party promissory notes and for general corporate purposes, including working capital.
- The company executed an underwritten public offering in August 2025, issuing 1,750,000 shares of common stock at $2.50 per share, which generated gross proceeds of $4.375 million for working capital and general corporate purposes. Additionally, warrants for up to 52,500 shares were granted to the underwriter.
- In 2025, stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the number of shares available for issuance and authorizing up to 1,000,000 shares of preferred stock, indicating potential future issuances.
Inbound Investments
- Synergy CHC secured a $20 million term loan credit agreement with ACP Agency, LLC in June 2025. At closing, $15 million was drawn, with an additional $2.5 million delayed draw facility and a $2.5 million uncommitted term loan incremental facility also available. These funds were primarily used to reduce existing debt and provide growth capital.
- A "$4 million equity raise" in late 2025 was noted to have fortified the company's balance sheet and positioned it for growth in 2026.
Outbound Investments
- In July 2021, Synergy CHC acquired Hand MD Corp. as a wholly-owned subsidiary.
Capital Expenditures
- Capital expenditures were reported as $0.0 for the fiscal years ending December 31, 2020, 2022, 2023, and 2024.
- However, quarterly data shows capital expenditures of $1 million for the quarter ending December 31, 2024, and $2 million for the quarter ending September 30, 2025.
Trade Ideas
Select ideas related to SNYR.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 17.76 |
| Mkt Cap | 0.4 |
| Rev LTM | 1,014 |
| Op Inc LTM | 71 |
| FCF LTM | 37 |
| FCF 3Y Avg | 59 |
| CFO LTM | 58 |
| CFO 3Y Avg | 104 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -0.2% |
| Rev Chg 3Y Avg | -0.6% |
| Rev Chg Q | 1.2% |
| QoQ Delta Rev Chg LTM | 0.3% |
| Op Inc Chg LTM | 12.2% |
| Op Inc Chg 3Y Avg | -0.4% |
| Op Mgn LTM | 5.8% |
| Op Mgn 3Y Avg | 7.9% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 6.0% |
| CFO/Rev 3Y Avg | 6.5% |
| FCF/Rev LTM | 4.1% |
| FCF/Rev 3Y Avg | 4.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.4 |
| P/S | 0.4 |
| P/Op Inc | 5.4 |
| P/EBIT | 5.9 |
| P/E | 10.8 |
| P/CFO | 7.3 |
| Total Yield | 5.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 7.7% |
| D/E | 0.6 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.5% |
| 3M Rtn | -9.6% |
| 6M Rtn | -7.1% |
| 12M Rtn | -2.9% |
| 3Y Rtn | 3.7% |
| 1M Excs Rtn | -6.6% |
| 3M Excs Rtn | -14.6% |
| 6M Excs Rtn | -14.6% |
| 12M Excs Rtn | -33.8% |
| 3Y Excs Rtn | -74.1% |
Price Behavior
| Market Price | $0.33 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 05/29/2014 | |
| Distance from 52W High | -91.8% | |
| 50 Days | 200 Days | |
| DMA Price | $0.91 | $3.06 |
| DMA Trend | down | down |
| Distance from DMA | -64.3% | -89.3% |
| 3M | 1YR | |
| Volatility | 87.8% | 89.6% |
| Downside Capture | 2.32 | 1.22 |
| Upside Capture | -400.94 | -55.53 |
| Correlation (SPY) | 1.5% | 10.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 4.07 | 0.14 | 0.07 | 0.47 | 0.84 | -28.93 |
| Up Beta | 5.34 | 3.94 | 3.38 | 1.16 | 0.89 | -0.64 |
| Down Beta | 9.38 | -2.84 | -1.15 | 0.23 | 0.97 | -30.05 |
| Up Capture | -386% | -290% | -236% | -111% | -24% | -6% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 4 | 12 | 20 | 50 | 111 | 161 |
| Down Capture | 2009% | 267% | 212% | 191% | 155% | -4588% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 18 | 28 | 40 | 66 | 129 | 204 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SNYR | |
|---|---|---|---|---|
| SNYR | -85.4% | 89.5% | -1.74 | - |
| Sector ETF (XLV) | 6.8% | 15.7% | 0.23 | 15.6% |
| Equity (SPY) | 27.8% | 12.5% | 1.73 | 11.2% |
| Gold (GLD) | 40.6% | 27.2% | 1.23 | 5.2% |
| Commodities (DBC) | 50.1% | 18.0% | 2.16 | 1.6% |
| Real Estate (VNQ) | 11.0% | 13.4% | 0.53 | 9.4% |
| Bitcoin (BTCUSD) | -17.3% | 42.2% | -0.34 | 3.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SNYR | |
|---|---|---|---|---|
| SNYR | -48.9% | 97.3% | -1.83 | - |
| Sector ETF (XLV) | 5.2% | 14.6% | 0.18 | 3.3% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | -1.0% |
| Gold (GLD) | 20.2% | 17.9% | 0.92 | 3.1% |
| Commodities (DBC) | 14.0% | 19.1% | 0.60 | -3.9% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.09 | 3.5% |
| Bitcoin (BTCUSD) | 7.9% | 56.2% | 0.35 | 1.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SNYR | |
|---|---|---|---|---|
| SNYR | -12.5% | 201.8% | 0.34 | - |
| Sector ETF (XLV) | 9.2% | 16.5% | 0.45 | 15.1% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 8.3% |
| Gold (GLD) | 13.4% | 15.9% | 0.70 | -1.0% |
| Commodities (DBC) | 9.6% | 17.7% | 0.45 | -1.2% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 9.5% |
| Bitcoin (BTCUSD) | 67.4% | 66.9% | 1.06 | -6.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/13/2025 | -6.4% | 10.4% | -7.5% |
| 8/14/2025 | -8.0% | -26.0% | -44.0% |
| 3/31/2025 | -19.0% | -20.9% | -34.5% |
| 12/6/2024 | -0.5% | 0.5% | -23.3% |
| SUMMARY STATS | |||
| # Positive | 0 | 2 | 0 |
| # Negative | 4 | 2 | 4 |
| Median Positive | 5.5% | ||
| Median Negative | -7.2% | -23.4% | -28.9% |
| Max Positive | 10.4% | ||
| Max Negative | -19.0% | -26.0% | -44.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 04/01/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 12/06/2024 | 10-Q |
| 03/31/2020 | 06/29/2020 | 10-Q |
| 12/31/2019 | 04/29/2020 | 10-K |
| 09/30/2019 | 11/14/2019 | 10-Q |
| 06/30/2019 | 08/13/2019 | 10-Q |
| 03/31/2019 | 05/03/2019 | 10-Q |
| 12/31/2018 | 03/29/2019 | 10-K |
| 09/30/2018 | 11/13/2018 | 10-Q |
| 06/30/2018 | 08/14/2018 | 10-Q |
| 03/31/2018 | 05/15/2018 | 10-Q |
| 12/31/2017 | 04/02/2018 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ross, Jack | CEO and Chairman | Direct | Buy | 7312025 | 3.69 | 100 | 369 | 1,514,771 | Form |
| 2 | Ross, Jack | CEO and Chairman | Direct | Buy | 7312025 | 3.66 | 250 | 915 | 1,502,090 | Form |
| 3 | Ross, Jack | CEO and Chairman | Direct | Buy | 7312025 | 3.90 | 350 | 1,365 | 1,599,612 | Form |
| 4 | Ross, Jack | CEO and Chairman | Direct | Buy | 7312025 | 3.83 | 300 | 1,149 | 1,569,561 | Form |
| 5 | Ross, Jack | CEO and Chairman | Direct | Buy | 7312025 | 3.54 | 300 | 1,062 | 1,449,655 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.